ArticleClinical and experimental gastroenterology2026
Omalizumab-Induced Remission and Steroid Withdrawal in Refractory Eosinophilic Gastroenteritis with Severe Hypereosinophilia: A Case Report.
Article in Clinical and experimental gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic gastroenteritis (EGE) is a rare, immune-mediated disorder characterized by pathological eosinophilic infiltration of the gastrointestinal tract. Corticosteroids are the primary treatment for EGE, but managing patients who are corticosteroid-dependent can be challenging. This report describes a 33-year-old female patient with EGE and severe hypereosinophilia, who was corticosteroid-dependent and had been on long-term oral corticosteroids for 5 years with an increasing maintenance dose. The patient achieved effective treatment with omalizumab without adverse reactions. This case provides evidence for the efficacy and safety of omalizumab in patients with corticosteroid-dependent eosinophilic gastroenteritis and severe hypereosinophilia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.